| cisplatin / Generic mfg. |
ChiCTR-OCC-15005888: The treatment of concurrent helical tomotherapy plus cetuximab followed by adjuvant chemotherapy for locally advanced nasopharyngeal carcinoma: a single-center and single arm phase II study |
|
|
| Completed | N/A | 46 | | Concurrent helical tomotherapy plus cetuximab followed by adjuvant chemotherapy with 4 cycles of cisplatin and docetaxel | Department of Otolaryngology Head and Neck Surgery, PLA General Hospital; PLA General Hospital, No | Nasopharyngeal carcinoma | | | | |
ChiCTR-IOR-16008633: A trial examining ginger to ameliorate the acute and delayed chemotherapy-induced nausea and vomiting among lung cancer patients receiving cisplatin based regimens |
|
|
| Recruiting | N/A | 146 | | ginger group ;corn placebo | Peking Union Medical College Hospital; Peking Union Medical College Hospital, Peking Union Medical College Hospital | Chemotherapy induced nausea &vomit | | | | |
ChiCTR-TRC-10000775: Phase I Study to Determine MTD of Docetaxel and Cisplatin with Concurrent Radiation Therapy for Stage III Non-Small Cell Lung Cancer |
|
|
| Completed | N/A | 11 | | concurrent chemotherapy consisted of Docetaxel 56 mg/m2 and Cisplatin 56 mg/m2, on day 1 and day 2, repeated every three weeks for a total of six weeks ;concurrent chemotherapy consisted of Docetaxel 60 mg/m2 and Cisplatin 60 mg/m2, on day 1 and day 2, repeated every three weeks for a total of six weeks ;concurrent chemotherapy consisted of Docetaxel 64 mg/m2 and Cisplatin 64 mg/m2, on day 1 and day 2, repeated every three weeks for a total of six weeks | Peking University School of Oncology, Beijing Cancer Hospital & Institute; Level of the institution：, NA | lung cancer | | | | |
ChiCTR-TRC-11001798: Randomized phase II trial comparing temozolomide plus cisplatin, high-dose interferon alpha-2b or observation in resectable mucosal melanoma patients |
|
|
| Completed | N/A | 189 | | observation ;inteferon ;Chemotherapy | Peking University Cancer Hospital and Institute; Peking University Cancer Hospital and Institute, the National Natural Science Foundation of China (30973483, 81172196, 81102068) | melenoma | | | | |
ChiCTR-TNC-10000823: Phase II trial of etoposide/cisplatin with RH-endostain for patients with extensive-stage small-cell lung cancer |
|
|
| Completed | N/A | 30 | | Cisplatin 25mg/m2 was administered intravenously over 30 to 60 minuteson on day 1-3; Etoposide 120mg/m2 was administered intravenously over 60 minutes on days 1-4; Endostar 15 mg was administered over 90 minutes by IV infusion on days 1-14; Repeated every 3 weeks for up to four cycles. | The First College Of Clinical Medical Science, China Three Gorges University ＆Yichang Central People's Hospital; The First College Of Clinical Medical Science, China Three Gorges University, self-funded | small-cell lung cancer | | | | |
| Completed | N/A | 215 | NA | Cisplatin injection, Atezolizumab injection | Shanghai Zhongshan Hospital, Fudan University, Shanghai Jiao Tong University School of Medicine | Urothelial Carcinoma | 08/20 | 11/22 | | |
ChiCTR-TRC-11001319: Peri-operative chemotherapy with ECX (epirubicin + cisplatin + capecitabine) or XP (capecitabine + cisplatin) in the treatment of advanced gastric cancer: a randomized, multicenter, parallel control |
|
|
| Completed | N/A | 100 | | Preoperative chemotherapy of ECX for 3 cycles (Epirubicin 50mg/m2 on day 1; capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2-4 weeks, and postoperative chemotherapy of ECX for 3 cycles 4-6 weeks after surgery. ;Preoperative chemotherapy of XP for 3 cycles(capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2-4 weeks, and postoperative chemotherapy of XP for 3 cycles 4-6 weeks after surgery. | Zhejiang Cancer Hospital; Zhejiang Cancer Hospital, Zhejiang Cancer Hospital | gastric cancer | | | | |
ChiCTR-OCS-13003599: Cisplatin plus hyperthermia kills Hepg2 cells in intraoperative blood salvage but preserves the function of erythrocytes |
|
|
| Completed | N/A | 200 | | chemtherapy ;heat plus chemtherapy | the Second Affiliated Hospital, School of Medicine, Zhejiang University; the Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Province-Health Ministry co-construction | cell salvage during tumor surgery | | | | |
ChiCTR-TRC-13004184: The radiation toxicty of Non-squamous Cell Lung Cancer patients by irradiation combined with pemetrexed |
|
|
| Completed | N/A | 100 | | Pemetrexed/platinum ;Docetaxel/Cisplatinl | GuiZhou Cancer Hospital; Level of the institution：, Sci-Tech Office of Guizhou Province | lung cancer | | | | |
ChiCTR-OOC-15006656: Phase II Study of CEPSP Chemotherapy for Newly Diagnosed Stage IV Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type |
|
|
| Completed | N/A | 21 | | Cisplatin 8-10mg/m^2 d1-5,d29-33; Etoposide 100mg/m^2 d1-5,d29-33; Pingyangmycin 10mg d1-5,d29-33;Semustine po,75-150 mg/m^2 d1; Prednisone po,25mg/m^2 d1-14(from the 11th day half a decline).Repeated dosing every 29 days(except semustine).Temporal shallow artery intubation administration (first cycle)+intravenous administration (from 2 to 6 cycle) | Department of Oral and Maxillofacial Surgery, Stomatological Hospital of Xi’an Jiaotong University; Stomatological Hospital of Xi’an Jiaotong University, The Fundamental Research Funds for the Central Universities” (Project No. 0818-08143011) | NK/T lymphoma (IV stage) | | | | |
ChiCTR-ICR-15006304: A double-blind, randomized, placebo-controlled clinical trial of tumor cells derived microparticles encapsulated methotrexate or normal saline intrapleural infusion combined with systemic chemotherapy of PP (pemetrexed / cisplatin) in the treatment of malignant pleural effusion of advanced non-small cell lung cancer except squamous cell carcinoma |
|
|
| Recruiting | N/A | 120 | | PP+MTX-microparticles intrapleural infusion ;PP+Normal saline intrapleural infusion | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, supported by Hubei Soundny Bio-Tech CO., LTD | Malignant Pleural Effusion | | | | |
NCT05890859: Lean Body Mass in Head and Neck Cancer Patients During Cisplatin-based Chemoradiation |
|
|
| Completed | N/A | 48 | Europe | DXA scan, Physical testing | Department of Public Health, Denmark | Head and Neck Cancer Patients, Lean Body Mass, Body Composition Changes | 07/17 | 05/23 | | |
PIPAC/PITAC, NCT02720835: Efficacy and Safety of in Gastric,Ovarian, Colorectal Cancer and Mesothelioma With Pleural Carcinomatosis. |
|
|
| Recruiting | N/A | 200 | Europe | pressurized intraperitoneal/intrathoracal aerosol chemoTx, PIPAC/PITAC | Othmar Schoeb | Colorectal Cancer, Ovarian Cancer, Gastric Cancer, Mesothelioma | 02/18 | 02/18 | | |
ChiCTR-IOR-15006875: Nimotuzumabcombined paclitaxel and cisplatin first-line treatment of metastatic esophageal squamous cell carcinomas of the prospective, multicenter, double-blind, randomized, controlled clinical study |
|
|
| Recruiting | N/A | 508 | | Duly, bead single + cisplatin + purple shirts alcohol resistance ;Cisplatin plus paclitaxel | The tumor hospital of Beijing university The tumor hospital affiliated to sun yat-sen university; The tumor hospital of Beijing university, The company funded | esophagus cancer | | | | |
ChiCTR1800017986: Tumor cell derived microparticles mediated chemotherapy combined radiotherapy for locally advanced non-small cell lung cancer |
|
|
| Recruiting | N/A | 10 | | Intravenous injection of cisplatin-microparticles with synchronous local radiotherapy | 5th Hospital of Wuhan; 5th Hospital of Wuhan, Science and technology program of Hubei provincial health and family planning commission (No. WJ2015MA018). | Cancer | | | | |
ChiCTR-ICR-15006536: Studies of 5% Ethanol-Cisplatin-Iodized oil in Treatments of Lung cancer, Liver cancer, Pancreatic cancer, Malignant pleural effusion and Ascites |
|
|
| Not yet recruiting | N/A | 144 | | 5% Ethanol-Cisplatin-Iodized oil treatment combinate with chemotherapy ;second-line chemotherapy | Beijing Tsinghua Changgung Hospital; Beijing Tsinghua Changgung Hospital, Beijing Tsinghua Changgung Hospital | Lung cancer，Liver cancer, Pancreatic cancer, Malignant pleural effusion and Ascites | | | | |
ChiCTR-ONC-16009325: Clinical study of irinotecan and platinum sequential chemotherapy with EP in the treatment of extensive stage small cell lung cancer |
|
|
| Not yet recruiting | N/A | 40 | | Etoposide (VP-16), 100/m2, intravenous drip, D1 ~ D3; cisplatin (DDP), 25 mg/m2, intravenous drip, D1 ~ D3 days. 21 d for 1 cycles, 4 cycles. | Huangshi Central Hospital; Huangshi Central Hospital, Self-financing | small cell lung cancer | | | | |
ChiCTR-IPR-17012144: A pilot randomized controlled trial for comparing CDA-II in Combination With DT-PDCE versus DT-PDCE Alone in Subjects with Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | N/A | 50 | | Dexamethasone 40 mg / d, oral, 4 d; thalidomide 100-200 mg / d, D1-4; cisplatin 10 mg / m2, D1-4; Pegylated liposomal doxorubicin 40 mg / m2, D1; Cyclophosphamide 400mg / m2, D1-4; Etoposide 40mg / (m2d), D1-4; Uroacitides Injection 300ml / d, D1-D7. ;Dexamethasone 40 mg / d, oral, 4 d; thalidomide 100-200 mg / d, D1-4; cisplatin 10 mg / m2, D1-4; Pegylated liposomal doxorubicin 40 mg / m2, D1; Cyclophosphamide 400mg / m2, D1-4; Etoposide 40mg / (m2d), D1-4 | Henan Cancer Hospital; Henan Cancer hospital, Self-financing | Relapsed or Refractory Multiple Myeloma | | | | |
NCT03240835: The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC Patients |
|
|
| Active, not recruiting | N/A | 50 | RoW | cisplatin and docetaxel, IMRT | Zhao Chong, Wu Jieping Medical Foundation | Nasopharyngeal Carcinoma, Malnutrition | 12/18 | 12/23 | | |
ChiCTR-ONN-17014070: The application of internal iliac artery infusion chemotherapy in patients with advanced ovarian cancer |
|
|
| Not yet recruiting | N/A | 200 | | (Paclitaxel + cisplatin) intravenous chemotherapy plus arterial infusion of cisplatin (the second, fourth and sixth cycle) ;(Paclitaxel + cisplatin) intravenous chemotherapy | The Obstetrics & Gynecology Hospital of Fudan University; The Obstetrics & Gynecology Hospital of Fudan University, Hospital development center,shanghai | Ovarian Cancer | | | | |
NCT03360760: Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum |
|
|
| Recruiting | N/A | 100 | RoW | Doxorubicin, Adriamycin, Cisplatin, cisplatinum, platamin, Methotrexate, HD-MTX, Ifosfamide, ifosphamide, definitive surgery, pre surgical chemotherapy, neoadjuvant chemotherapy | Peking University People's Hospital | Osteosarcoma of Pelvis | 02/20 | 02/25 | | |
ChiCTR1800016319: Clinical study of raltitrexed and cisplatin combined intensity modulated conformal radiotherapy for locally advanced esophageal cancer |
|
|
| Recruiting | N/A | 90 | | Cisplatin + raltitrexet combined with intensity modulated conformal radiation therapy ;Cisplatin+5-FU Combined with Intensity Conformal Radiation Therapy | The first hospital of China Medical University; The first hospital of China Medical University, The SCI fund of the department of radiotherapy of the first hospital of China Medical University | Esophageal cancer | | | | |
ChiCTR1900023373: Phase I Clinical Study for Postoperative Early Stage Cervical Cancer with High Risk Factors Treated by Albumin Paclitaxel and Cisplatin Chemotherapy Combined with Synchronous Local Radiotherapy |
|
|
| Recruiting | N/A | 24 | | Albumin Paclitaxel and Cisplatin Chemotherapy Combined with Synchronous Local Radiotherapy | West China Hospital, Sichuan University; Level of the institution：, CSPC OUYI PHARMACEUTICAL CO.，LTD. | Cervical cancer | | | | |
ChiCTR2100043233: Efficacy of Chemotherapy Combined with Anlotinib for the Second Line Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck: a Retrospective Study Based on Medical Records |
|
|
| Recruiting | N/A | 260 | | paclitaxel combined with cisplatin plus an Anlotinib ;paclitaxel combined with cisplatin | Daping Hospital, Army Medical University; Daping Hospital, Army Medical University, self -finance | head and neck squamous cell carcinoma | | | | |
ChiCTR2000038795: Retrospective analysis of the effect of neoadjuvant chemotherapy on the prognosis of patients with hypopharyngeal carcinoma |
|
|
| Not yet recruiting | N/A | 126 | | 1. Nimotuzumab 300mg/m2 i.v d1; Cisplatin 50 mg/m2 (total <=50mg) i.v. d1; 5-FU 750mg/m2/day i.v. d1-5; 21d×2cycles; 2. Surgical treatment; 3. Postoperative radiotherapy ;1. Cisplatin 50 mg/m2 (total <=50mg) i.v. d1; 5-FU 750mg/m2/day i.v. d1-5; 21d*2cycles; 2. Surgery treatment; 3. Postoperative radiotherapy | Shanghai General Hospital; Shanghai General Hospital, Self-financing | Hypopharyngeal squamous cell carcinoma | | | | |
NCT02627807: Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | N/A | 386 | RoW | IMRT using individualized CTV, IMRT using traditional CTV, Gemcitabine and cisplatin (induction chemotherapy), Gemcitabine and cisplatin (GP), Docetaxel and cisplatin (induction chemotherapy), Docetaxel and cisplatin (TP), Cisplatin 100mg/m² concurrent chemotherapy, DDP 100mg/m², Cisplatin 80mg/m² concurrent chemotherapy, DDP 80mg/m² | Sun Yat-sen University | Nasopharyngeal Neoplasms | 12/20 | 12/22 | | |
| Recruiting | N/A | 196 | RoW | CRT, concurrent chemoradiotherapy, surgery, esophagectomy | The First Affiliated Hospital of Henan University of Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Anyang Tumor Hospital, 150th Hospital of PLA | Esophagus Cancer | 12/20 | 06/21 | | |
ChiCTR-OPC-17012997: Assessment of ATM and NF-κB activities in cultured peripheral blood mononuclear cells for predicting adverse events in patients treated with radiotherapy or chemotherapy |
|
|
| Not yet recruiting | N/A | 230 | | 0.5, 1, 1.5, 2, 2.5Gy X-ray exposure + Gemcitabine Combined with cisplatin | Cancer Center, The First Bethune Hospital of Jilin University; The First Bethune Hospital of Jilin University, The National Natural Science Fund | cancer | | | | |
NCT04511351: Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma |
|
|
| Recruiting | N/A | 76 | RoW | Chidamide | Chinese Academy of Medical Sciences | Lymphoma | 12/20 | 12/20 | | |
| Not yet recruiting | N/A | 144 | NA | Jing-yan-kang Granule, PC chemotherapy and symptomatic treatment | Henan University of Traditional Chinese Medicine | Lung Adenocarcinoma | 12/20 | 06/22 | | |
NCT04588090: A Prospective Randomized Controlled Study of Radiotherapy and the Concurrent Three-week and Single-week TP Chemotherapy for Advanced Cervical Squamous Cell Carcinoma and the Correlation Between HPV Classification and Sensitivity. |
|
|
| Active, not recruiting | N/A | 200 | RoW | The concurrent 3 weeks TP regimen, The concurrent weekly TP regimen, External radiation plus intraluminal after-loading irradiation | Chongqing University Cancer Hospital | Cervical Cancer | 01/21 | 05/21 | | |
TUO-UR-21-01, NCT06358599: The Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Patients With Variant Histologies Bladder Cancer Who Underwent Radical Cystectomy |
|
|
| Completed | N/A | 221 | RoW | Cisplatin, neoadjuvant cisplatin containing combination chemotherapy | Ankara Etlik City Hospital | Bladder Cancer, Bladder Cancer Stage I, Bladder Cancer Stage II | 10/23 | 01/24 | | |
NCT03514849: Clinical Study of Combined Radical Operation With Postoperative Adjuvant Chemotherapy and Prophylactic Cranial Irradiation in pT1-2N0M0 Stage of Small Cell Lung Cancer |
|
|
| Recruiting | N/A | 360 | RoW | prophylactic cranial irradiation (PCI), lobectomy + mediastinal lymph node dissection or systematic lymph node sampling, postoperative adjuvant chemotherapy | Peng Zhang | Small-cell Lung Cancer | 03/21 | 03/26 | | |
ChiCTR2000033034: Efficacy and Safety of Neoadjuvant Anlotinib Plus Pemetrexed and Cisplatinum in Patients With Unresectable Stage IIIA Lung Adenocarcinoma |
|
|
| Recruiting | N/A | 60 | | Chemotherapy plus anlotinib ;chemotherapy group | He'nan Provincial Chest Hospital; He'nan Provincial Chest Hospital, self-raised | Non-small cell lung cancer | | | | |
NCT04867330: Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC |
|
|
| Recruiting | N/A | 46 | RoW | Toxicities reduced treatment arm | Fudan University | Oropharyngeal Carcinoma, Immune Checkpoint Inhibitor, De-escalation | 05/21 | 01/26 | | |
NCT02512692: 90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Active, not recruiting | N/A | 6 | US | SIR-Spheres microspheres (Yttrium-90 Microspheres), 90Y TARE, Gemcitabine, Cisplatin | Medical University of South Carolina | Intrahepatic Cholangiocarcinoma | 05/21 | 08/22 | | |
ChiCTR1900023771: Study for apatinib plus EP in the first line treatment of patients with extensive-stage small-cell lung cancer |
|
|
| Not yet recruiting | N/A | 30 | | Apatinib 250mg po, qd, q3w, continuous taken; EP: Etoposide: 100mg/ m2, d1-3, q3w, 4-6 cycles; Cisplatin: 75 mg/ m2, d1, q3w, 4-6 cycles | Tangshan People's Hospital; Tangshan People's Hospital, self-raise | small-cell lung cancer | | | | |
ChiCTR1900025644: Multicenter, open, single-arm Clinical Study to Evaluate the Efficacy and Safety of Sintilimab Plus Chemotherapy (Cisplatin or Carboplatin+ Paclitaxel) as First-Line Treatment in Patients With Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma (R/M SCCHN) |
|
|
| Recruiting | N/A | 61 | | Sintilimab Plus Chemotherapy | Shanghai East Hospital; Shanghai East Hospital, East Clinical Center of Oncology, ECCO | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | | | | |
NCT02985658: Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer |
|
|
| No Longer Available | N/A | | US | Veliparib, ABT-888, Cisplatin, Platinol-AQ, Platinol, Vinorelbine, Navelbine | University of Washington, AbbVie | Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer | | | | |
ChiCTR1900022162: Transcutaneous electroacupuncture (TEA) at BL21 in alleviating cisplatin associated dyspepsia symptom |
|
|
| Not yet recruiting | N/A | 60 | | transcutaneous electroacupuncture ;sham-TEA | The 1st Affiliated Hospital of Xi'an Jiaotong University; The 1st Affiliated Hospital of Xi'an Jiaotong University, The 1st Affiliated Hospital of Xi'an Jiaotong University | chemotherapy associated dyspepsia syndrome | | | | |
NCT04132882: A Compassionate Use Program to Provide Access to Sodium Thiosulfate |
|
|
| Available | N/A | | RoW | Sodium Thiosulfate (STS) | TRPHARM, Fennec Pharma | Cisplatin-Induced Hearing Loss in Children Who Had Standard-risk Hepatoblastoma | | | | |
GASPACCO, NCT04595929: Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt- |
|
|
| Recruiting | N/A | 304 | RoW | Staging laparoscopy, 5-Fluorouracil, 5-FU, Leucovorin, Calciumfolinat, Oxaliplatin, Docetaxel, Radical surgery, PIPAC, Adjuvant chemotherapy | St. Petersburg State Pavlov Medical University | Peritoneal Carcinomatosis, Gastric Cancer | 10/21 | 01/29 | | |
NCT03750539: Chemotherapy and Pelvic Hypofractionated Radiation Followed by Surgery Cervical Cancer |
|
|
| Recruiting | N/A | 100 | RoW | Standard radiotherapy, hypofractionated radiotherapy, Radical hysterectomy, Surgery | National Institute of Cancerología | Cervix Cancer | 11/24 | 11/25 | | |
NCT05423704: Feasibility of Patient Selection and Treatment of Head-neck Cancer With Proton Therapy in Denmark |
|
|
| Active, not recruiting | N/A | 63 | Europe | Proton radiotherapy | Danish Head and Neck Cancer Group | Head-and-neck Cancer | 11/21 | 05/26 | | |
ChiCTR2000034840: A Study of Camrelizumab in Combination With Pemetrexed and Carboplatin /Cisplatin in Subjects With Lung Adenocarcinoma After Radiofrequency Ablation |
|
|
| Recruiting | N/A | 30 | | Camrelizumab, Pemetrexed, Carboplatin /Cisplatin | Beijing Chao-Yang Hospital Affiliated to Capital Medical University; Beijing Chao-Yang Hospital Affiliated to Capital Medical University, raise independently | Lung Adenocarcinoma | | | | |
ChiCTR1900027168: Comparing Toripalimab With Combination Chemotherapy and Chemotherapy Alone in Treating Participants With Locally Advanced or Metastatic Small Cell Cancers of Urinary System |
|
|
| Not yet recruiting | N/A | 40 | China | Toripalimab, Cisplatin and Etoposide ;Cisplatin and Etoposide | Shanghai Changhai Hospital ; Shanghai Changhai Hospital, No sponsor | Small Cell Carcinoma of Urinary System | | | | |
ChiCTR1800017108: A randomized controlled trial of Nedaplatin versus Cisplatin concurrent chemoradiotherapy in patients with cervical cancer |
|
|
| Completed | N/A | 160 | | nidaplatin ;cisplatin | Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Municipal Health Commission | cervical cancer | | | | |
ChiCTR1900022364: A clinical study for recombinant human vascular endostatin intravenous injection combined with chemotherapy in the treatment of exogenous recurrent metastatic head and neck malignant tumor |
|
|
| Recruiting | N/A | 36 | | Chemotherapy + intravenous injection of recombinant human vascular endostatin (30mg/ m, d1-7 daily). The needle was injected at 0.5cm subcutaneously at the outer edge of the tumor body, and then the needle was sneaked subcutaneously to the tumor center. No blood was drawn back, and the drug was injected ;Chemotherapy + recombinant human endostatin was pumped into the group (recombinant human endostatin 30mg/ m, d1-d7). Recombinant human endostatin was added into normal saline and made into 220ml, using portable infusion pump with a speed of 2ml/h and continuous uniform intravenous pumping. ;Chemotherapy alone group (chemotherapy docetaxel 75 mg/ m,d1, cisplatin 30mg/ m,d1-3) | The Second Xiangya Hospital of Central South University; The Second Xiangya Hospital of Central South University, China International Medical Foundation | Head and Neck Malignancies | | | | |
ChiCTR2000038999: Observation of the Clinical Efficacy of 'Niejin-Maiwei' Massage to Prevent the Digestive Tract Adverse Reaction Caused by Chemotherapy Regimens which Include Cisplatin |
|
|
| Recruiting | N/A | 68 | | 'Niejin-Maiwei' Massage ;sham massage | Guang'anmen Hospital, China Academy of Chinese Medical Sciences; Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Special Fund for Scientific Research of National TCM Clinical Research Demonstration Base | Chemotherapy-induced neutropenia | | | | |
ChiCTR1900023657: A clinical trial for apatinib combination with nab-paclitaxel /cisplatin in the treatment of NSCLC |
|
|
| Not yet recruiting | N/A | 60 | | Apatinib 250mg Po qd nab-paclitaxel: 100mg/m2 iv d1, 8, 15 cisplatin: 75mg/m2 d1 q3w, 4-6 cycles | Tangshan People's Hospital; Tangshan People's Hospital, no | non small cell lung cancer | | | | |
ChiCTR1900026322: Preventive value of limb ischemic preconditioning on nephrotoxicity of cisplatin |
|
|
| Not yet recruiting | N/A | 60 | | LIPC+Sham LIPC ;Sham LIPC+LIPC | Changzhou second people's Hospital; Changzhou Second People's Hospital, The National Natural Science Fund | Nephrotoxicity of cisplatin | | | | |
ChiCTR2000029011: Anlotinib Maintenance Therapy for Patients With Extensive-Stage Small Cell Lung Cancer and Without Progression After First-Line Etoposide and Cisplatin Chemotherapy: a Monocentric, Single Arm Study |
|
|
| Recruiting | N/A | 37 | | Anrotinib | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Enterprise Support | Extensive-Stage Small Cell Lung Cancer | | | | |
ChiCTR2000041078: The mechanism of NTNG1 promotes cisplatin resistance in ovarian cancer |
|
|
| Recruiting | N/A | 67 | | Nil ;Nil | The Second Affiliated Hospital, Chongqing Medical University; The Second Affiliated Hospital， Chongqing Medical University, NSFC | ovarian cancer | | | | |
ChiCTR-IOR-17010374: Prospective, randomized, multicenter clinical trial of cisplatin concurrent chemotherapy for single-week versus three-weeks regimens of locally advanced cervical cancer with radical chemoradiotherapy |
|
|
| Not yet recruiting | N/A | 100 | | Cisplatin concurrent chemotherapy for single-week ;Cisplatin concurrent chemotherapy for three-weeks | China-Japan Union Hospital of Jilin University; China-Japan Union Hospital of Jilin University, Self-financing | cervical cancer | | | | |
ChiCTR2100043896: The mechanism of RPL-23 promoting cisplatin resistance in ovarian cancer cells |
|
|
| Recruiting | N/A | 50 | | Nil | The Second Affiliated Hospital of Nanchang University; The Second Affiliated Hospital of Nanchang University, self-raised | ovarian cancer | | | | |
ChiCTR2100045484: Nituzumab-albumin-bound paclitaxel and cisplatin therapy Single arm study of recurrent/metastatic cervical squamous cell carcinoma |
|
|
| Recruiting | N/A | 30 | | Nituzumab treatment regimen | Baotou Tumor Hospital; Baotou Tumor Hospital, Enterprise financing | Recurrent/metastatic cervical squamous cell carcinoma | | | | |
ChiCTR1900022816: Clinical study for compound gossypol acetate tablets combined with docetaxel and cisplatin in the treatment of advanced lung adenocarcinoma with high expression of LRPPRC protein |
|
|
| Not yet recruiting | N/A | 60 | | Gossypol acetate tablets combined with docetaxel and cisplatin ; Docetaxel combined with cisplatin | Tangshan People's Hospital; Tangshan People's Hospital, Self-raised | Lung adenocarcinoma | | | | |
ChiCTR2100052788: a real world study about efficacy and safety of atezolizumab plus chemotherapy in extensive stage small cell lung cancer |
|
|
| Recruiting | N/A | | | Subject to standard treatment regimen of atezolizumab + carboplatin/cisplatin + etoposide ;Standard chemotherapy regimen of carboplatin/cisplatin + etoposide | Beijing Cancer Hospital; Beijing Cancer Hospital, Beijing Hengji Health Management Development Foundation | small cell lung cancer (SCLC) | | | | |
ALT-SCLC-02, NCT04731909: Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer |
|
|
| Recruiting | N/A | 80 | RoW | Toripalimab, Toripalimab Injection, Teruipuli dankang Zhusheye, TuoYI, JS001, Anlotinib, Anlotinib Hydrochloride Capsules, FuKeWei, Cisplatin, Cisplatin injection, Carboplatin, Carboplatin injection | Third Military Medical University | SCLC, Extensive Stage, Lung Cancer, Small Cell Lung Cancer | 06/22 | 06/23 | | |
ChiCTR1900024298: Open randomized clinical study of Pembrolizumab combination with albumin-bound taxol and cisplatin in the treatment of advanced relapsed metastatic squamous cell carcinoma of the head and neck |
|
|
| Not yet recruiting | N/A | 60 | China | Pembrolizumab combined with albumin taxol plus cisplatin ;albumin taxol and cisplatin | The Second Xiangya Hospital of Central South University ; The Second Xiangya Hospital of Central South University, Xisike-CSPC Clinical Oncology Research Foud | Head and Neck Malignancies | | | | |
GETUGV04, NCT01495676: A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer |
|
|
| Active, not recruiting | N/A | 69 | Europe | Radiation + cisplatin, Radiation + cisplatin + gemcitabine | Institut du Cancer de Montpellier - Val d'Aurelle | Infiltrating Bladder Urothelial Carcinoma | 07/22 | 09/25 | | |
NCT02640898: Docetaxel-based Chemoradiotherapy Plus Periradiation Chemotherapy Compared With INT 0116 Adjuvant Arm in Gastric Cancer |
|
|
| Recruiting | N/A | 500 | RoW | docetaxel-based chemoradiotherapy, a docetaxel arm, FU-based chemoradiotherapy, the INT 0116 adjuvant arm | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Gastric Cancer | 08/22 | 12/22 | | |
NCT00430313: Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin |
|
|
| Withdrawn | N/A | 100 | NA | Electro-Stimulation of Yongquan (K1) Acupoint, ES | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Liver Cancer, Liver Metastasis | 08/22 | 08/22 | | |
ChiCTR2100042243: Human lung carcinoma cell-derived microparticles packaging methotrexate to treat malignant pleural effusion: a randomized parallel controlled clinical study. |
|
|
| Recruiting | N/A | 92 | | Human lung carcinoma cell-derived microparticles packaging methotrexate intrapleural infusion ;Cisplatin intrapleural infusion | Union Hospital, Tongji Medical College, Huazhong University of Science & Technology; Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Supported by Hubei Soundny Bio-Tech Co., Ltd. | Malignant Pleural Effusion | | | | |
ChiCTR2000037164: Chuan Huang Fang control including cisplatin renal impairment caused by chemotherapy of clinical research |
|
|
| Recruiting | N/A | 106 | | chemotherapy ;chemotherapy+Chuan Huang Fang | Shanghai Municipal Hospital of Traditional Chinese Medicine; Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai Hospital Development Center | Renal impairment | | | | |
NCT04747717: Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer |
|
|
| Recruiting | N/A | 30 | RoW | chemotherapy/surgery | N.N. Petrov National Medical Research Center of Oncology | Ovarian Cancer | 10/22 | 10/25 | | |
ChiCTR2000038460: Canceled by the investigator A Clinical Study for the Efficacy and Safety of Camrelizumab combined with chemotherapy as the first-line treatment with locally advanced/metastatic (IIIB-IV) squamous non-small cell lung cancer |
|
|
| Suspended | N/A | 20 | | Camrelizumab: 200mg, iv, 30min, q3w, 24 months Paclitaxel For Injection (Albumin Bound): 260mg/ m2 iv d1; or Paclitaxel: 175mg/m2 iv d1; q3w, 4-6 cycles, Carboplatin: AUC=5-6, iVd1; or Cisplatin75mg/m2 iv d1; q3w, 4-6 cycles | Xingtai People's Hospital; Xingtai People's Hospital, self-financing | squamous non-small cell lung cancer | | | | |
| Recruiting | N/A | 53 | RoW | Preventive photobiomodulation Therapy (PBMT), Preventive Low Power Laser Therapy (TLBP ) | Instituto Nacional de Cancer, Brazil | Mucositis Oral | 06/25 | 07/25 | | |
ChiCTR2000040942: The efficacy and safety of auricular acupuncture versus electroacupuncture in ameliorating chemotherapy-induced nausea and vomiting among patients receiving cisplatin-based regimens |
|
|
| Recruiting | N/A | 120 | | auricular acupuncture ;electroacupuncture ;standard treatment | Chengdu Second People's Hospital; Chengdu Second People's Hospital, Chengdu Municipal Health Commission | Chemotherapy-induced nauses and vomiting | | | | |
ChiCTR1800017310: A randomized controlled trial for arsenic trioxide combined with ESHAP (etoposide+methylprednisolone+cytarabine+cisplatin) in the treatment of relapsed or refractory ALK+ anaplastic large cell lymphoma. |
|
|
| Recruiting | N/A | 58 | | Etoposide 60mg/m2/d d1-4; Methylprednisolone 500mg/d d1-4; Cytarabine 2g/m2/Q12h d5; Cisplatin 25mg/m2/d d1-4 ;Etoposide 60mg/m2/d d1-4; Methylprednisolone 500mg/d d1-4; Cytarabine 2g/m2/Q12h d5; Cisplatin 25mg/m2/d d1-4; ATO 10mg/d d1-14 | Tongji Hospital Affiliated to Tongji University School of Medicine; Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai Municipal Health Planning Commission clinical research fund project | ALK+ anaplastic large cell lymphoma | | | | |
NCT03717610: Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer |
|
|
| Recruiting | N/A | 10 | Europe | radical surgery with HIPEC | Uppsala University Hospital, Uppsala University, The Netherlands Cancer Institute | Ovarian Cancer Recurrent | 12/22 | 12/22 | | |
ChiCTR1900024322: Establishment nasopharyngeal carcinoma organoid llibrary and individualized precision treatment of nasopharyngeal carcinoma |
|
|
| Not yet recruiting | N/A | 160 | | new antineoplastic drug ;cisplatin | Eye, Ear, Nose & Throat Hospital of Fudan University; Eye, Ear, Nose & Throat Hospital of Fudan University, Shanghai Science and Technology Commission Research Project | nasopharyngeal carcinoma | | | | |
NCT04158518: De-escalation Protocols in Locoregionally Advanced Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | N/A | 118 | RoW | Toxicities reduced treatment, Conventional treatment | Chaosu Hu | Nasopharyngeal Carcinoma | 12/22 | 12/22 | | |
ChiCTR2200056781: Feasibility study of early diagnosis markers for acute kidney injury caused by cisplatin chemotherapy |
|
|
| Not yet recruiting | N/A | | | | The Fifth Affiliated Hospital of Sun Yat-sen University; The Fifth Affiliated Hospital of Sun Yat-sen University, No funding support | Acute kidney injury | | | | |
NCT05248022: Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure |
|
|
| Not yet recruiting | N/A | 98 | NA | Drug-eluting beads bronchial arterial chemoembolization, Programmed Cell Death Protein 1 Inhibitor | The Central Hospital of Lishui City, Jiangxi Provincial Cancer Hospital, Jiangxi Chest Hospital, The First Affiliated Hospital of Zhengzhou University, Zhejiang University | Carcinoma, Non-Small-Cell Lung | 12/24 | 12/24 | | |
| Recruiting | N/A | 150 | RoW | Adjuvant chemotherapy | Fudan University | Bladder Cancer | 01/23 | 01/28 | | |
| Active, not recruiting | N/A | 98 | US | Specimen Ultra-High field MRI, chemotherapy, chemo, Cystectomy and Lymphadenectomy, surgery | University of Cincinnati | Bladder Cancer | 12/24 | 12/24 | | |
ChiCTR1900028010: An open phase I/II clinical study of Sintilimab combined with Cisplatin in the treatment of resectable stage II-IVa head and neck squamous cell carcinoma |
|
|
| Not yet recruiting | N/A | 31 | | sintilimab 200mg ivgtt q21d + cisplatin 80mg/m2 ivgtt q21d，treatment for two cycles before operation | Fujian Provincial Cancer Hospital; Fujian Provincial Cancer Hospital, Fujian Provincial Cancer Hospital | head and neck squamous cell carcinoma | | | | |
| Recruiting | N/A | 500 | Europe | neoadjuvant chemotherapy with cisplatine | University Hospital, Rouen, Institut Curie, APHP | Bladder Cancer, Chemotherapy Effect | 03/23 | 03/23 | | |
NCT05746598: Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer Patients |
|
|
| Recruiting | N/A | 178 | RoW | Cisplatin injection | Ain Shams University, Misr International University | Non Small Cell Lung Cancer, Nephropathy, Cardiotoxicity | 03/23 | 04/23 | | |
ChiCTR2100045038: Short-Term Efficacy of Local Iodine Pleurodesis Versus Intrapleural Perfusion of Recombinant Human Endostatin Combined with Cisplatin in the Treatment of Non-small Cell Lung Cancer Complicated With Malignant Pleural Effusion: a Randomized Clinical Study |
|
|
| Recruiting | N/A | 152 | | Intrapleural perfusion of endostar combined with cisplatin ;Iodophor was injected into the chest | Peking University First Hospital; Peking University First Hospital, None | Malignant pleural effusion from non-small cell lung cancer | | | | |
NCT04823468: Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 214 | RoW | Abbott®Ensure, Intensity Modulated Radiation Therapy, cisplatin | Jinsheng Hong, Fujian Cancer Hospital, The Second Affiliated Hospital of Fujian Medical University, The Nanping First Affiliated Hospital of Fujian Medical University, Quanzhou First Hospital Affiliated to Fujian Medical University, Fujian Medical University Union Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Hunan Cancer Hospital, Jiangxi Provincial Cancer Hospital, 900th hospital of the joint logistics team, PLA, Nanfang Hospital, Southern Medical University, The First Affiliated Hospital of Xiamen University, Zhongshan Hospital Xiamen University | Nasopharyngeal Carcinoma, Nutritional Support | 07/25 | 09/25 | | |
| Active, not recruiting | N/A | 707 | Europe | neoadjuvant chemotherapy with cisplatine | University Hospital, Rouen, Institut Curie | Bladder Cancer, Genomic Instability | 03/26 | 03/26 | | |
ChiCTR1900025318: Exploratory clinical study for the neoadjuvant therapy of PD-1 antibody combined with paclitaxel and cisplatin for operable esophageal squamous cell carcinoma |
|
|
| Not yet recruiting | N/A | 35 | | PD-1 antibody; Paclitaxel combined with cisplatin chemotherapy; Radical resection of esophageal cancer through two incisions of right thoracic and upper abdomen. | Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, 朱敬华医师：请说明经费来源 | Esophageal squamous cell carcinoma | | | | |
NCT03662841: Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma |
|
|
| Terminated | N/A | 11 | RoW | Ablative chemoembolization (ACE) | Chinese University of Hong Kong | Carcinoma, Hepatocellular | 04/23 | 04/23 | | |
ChiCTR2100044971: Efficacy and safety of Camrelizumab plus gemcitabine and cisplatin as first-line therapy for recurrent / refractory nasopharyngeal cancer |
|
|
| Recruiting | N/A | 33 | | camrelizumab combined with gemcitabine and cisplatin as first line therapy | Huadong Hospital affiliated to Fudan University; Huadong Hospital affiliated to Fudan University, HENGRUI MEDCINE | nasopharyngeal carcinoma | | | | |
NCT05821192: Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma. |
|
|
| Recruiting | N/A | 34 | RoW | Rituximab, Gemcitabine, Dexamethasone, Cisplatin, PD-1 monoclonal antibody | Ou Bai, MD/PHD, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University | Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma | 04/23 | 12/24 | | |
NCT05640817: Nephroprotective Effect of Pentoxifylline Against Cisplatin in Patients With Head and Neck Cancer |
|
|
| Not yet recruiting | N/A | 90 | NA | Pentoxifylline 400 mg SR tablets, cisplatin with standard hydration with normal saline | Tanta University | Pentoxifylline, Cisplatin, Nephrotoxixcity | 05/23 | 06/23 | | |
BETTER, NCT05407155: Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | N/A | 56 | NA | bevacizumab plus nab-paclitaxel and platinum | Fudan University | Non-small Cell Lung Cancer Metastatic | 06/23 | 06/24 | | |
ChiCTR2100047969: Comparison of therapeutic effects of brucea brucea oil emulsion injection and cisplatin injection in the treatment of malignant pleural effusion |
|
|
| Not yet recruiting | N/A | 128 | | Bruisea oil emulsion injection ;Cisplatin monotherapy | Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine; Jiangsu Jiuxu Pharmaceutical Co. Ltd., Jiangsu Jiuxu Pharmaceutical Co., Ltd. | Malignant pleural effusion | | | | |
NCT03523234: Neoadjuvant Therapy Combined With Radical Surgery for the Treatment of Small Cell Lung Cancer (SCLC) in II and IIIA Stage |
|
|
| Recruiting | N/A | 300 | RoW | neoadjuvant chemotherapy, radical surgery for stage II and IIIA small cell lung cancer (SCLC), prophylactic cranial irradiation, Chemotherapy | Peng Zhang | Small-cell Lung Cancer | 07/23 | 07/23 | | |
NCT05132790: Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment |
|
|
| Active, not recruiting | N/A | 24 | RoW | SHR-1316 at a dose 20mg/kg q3w, SHR6390 at a dose of 150mg orally, daily, SBRT | Shengjing Hospital, Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 12/24 | 12/28 | | |
ERI-Based-01, NCT05953909: A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (). |
|
|
| Active, not recruiting | N/A | 120 | RoW | Eribulin-Based Regimen, Not Applicable since observational study, nab-paclitaxel based regimen, Other Chemotherapy Regimen | Fujian Cancer Hospital | Breast Cancer | 08/23 | 08/23 | | |
NCT06262386: Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial |
|
|
| Recruiting | N/A | 358 | RoW | Cisplatin based chemottherapy | Chang Gung Memorial Hospital, National Science and Technology Council | Lung Cancer, Relapse/Recurrence | 07/28 | 07/28 | | |
ChiCTR2200061128: Single center, single arm, phase II clinical trial of albumin-bound paclitaxel combined with cisplatin as neoadjuvant therapy for locally advanced cervical cancer |
|
|
| Recruiting | N/A | 50 | | albumin-bound paclitaxel combined with cisplatin | Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences, CSPC Ouyi Pharmaceutical Co., Ltd. | cervical cancer | | | | |
NCT06430515: The Clinical Efficacy and Safety of Intratumoral Injection of Chemotherapy for Advanced Solid Tumors |
|
|
| Recruiting | N/A | 200 | RoW | Intratumoral Injection of Chemotherapy | Wuxi People's Hospital | Intratumoral Injection, Cancer | 12/27 | 12/28 | | |
NCT05792228: A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting |
|
|
| Completed | N/A | 92 | RoW | nurse-led standardized intervention | Tianjin Medical University Cancer Institute and Hospital | Squamous Cell Carcinoma of Head and Neck, Chemotherapy Induced Nausea and Vomiting | 10/23 | 10/23 | | |
SCENIC, NCT06292286: Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer |
|
|
| Recruiting | N/A | 18 | RoW | Carboplatin or cisplatin, Paraplatin or Platinol, Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar, Taxol, Gemzar, Caelyx, Bevacizumab or biosimilar, Avastin or mvasi, Cytoreductive surgery | The University of Hong Kong | Recurrent Ovarian Carcinoma | 12/25 | 07/26 | | |
| Enrolling by invitation | N/A | 2000 | RoW | neurosurgical resection, radiation, chemotherapy, target therapy | Sun Yat-sen University, Cancer Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region People's Hospital, First Affiliated Hospital of Guangxi Medical University | Brain Metastases | 11/23 | 11/24 | | |
NCT05677217: Clinical Feasibility of Nab-paclitaxel Plus Gemcitabine-cisplatin Chemotherapy in Locally Advanced Cholangiocarcinoma |
|
|
| Recruiting | N/A | 100 | RoW | | CHA University | Locally Advanced Cholangiocarcinoma | 09/24 | 11/24 | | |
